-
21.发明授权von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage 有权von Willebrand因子和因子VIII-聚合物缀合物具有可释放的连接公开(公告)号：US08133865B2
公开(公告)日：2012-03-13
申请号：US12006059
申请日：2007-12-27
申请人： Mary J. Bossard , Gayle Stephenson , Zhihao Fang , Harold Zappe , Stacy Mitchell , Ping Zhang , Friedrich Scheiflinger , Peter Turecek , Juergen Siekmann , Katalin Varadi , Herbert Gritsch
发明人： Mary J. Bossard , Gayle Stephenson , Zhihao Fang , Harold Zappe , Stacy Mitchell , Ping Zhang , Friedrich Scheiflinger , Peter Turecek , Juergen Siekmann , Katalin Varadi , Herbert Gritsch
IPC分类号： A61K38/36 , C07K14/755
CPC分类号： C07K14/755 , A61K47/60
摘要： The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
摘要翻译： 本发明提供了von Willebrand因子 - 聚合物共轭物和因子VIII-聚合物缀合物，其各自具有可释放的连接。 还提供了制备缀合物的方法，用于施用缀合物的方法。
-
22.发明申请METHODS FOR DETERMINING ACTIVE INGREDIENTS IN PRO-DRUG PEG PROTEIN CONJUGATES WITH RELEASABLE PEG REAGENTS (IN VITRO DE-PEGYLATION) 有权使用可释放的PEG试剂（在体外去PEG化）中测定丙型肝素PEG蛋白质结合物中活性成分的方法公开(公告)号：US20100112607A1
公开(公告)日：2010-05-06
申请号：US12582497
申请日：2009-10-20
申请人： Katalin Varadi , Gerald Schrenk , Hanspeter Rottensteiner , Peter Turecek , Alfred Weber , Heinz Anderle , Sean M. Culbertson , Zhihao Fang , Harold Zappe , Ping Zhang , Mary J. Bossard
发明人： Katalin Varadi , Gerald Schrenk , Hanspeter Rottensteiner , Peter Turecek , Alfred Weber , Heinz Anderle , Sean M. Culbertson , Zhihao Fang , Harold Zappe , Ping Zhang , Mary J. Bossard
CPC分类号： G01N33/68 , G01N33/542 , G01N33/582 , G01N33/86 , G01N2333/76
摘要： The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.
摘要翻译： 本发明涉及从用可逆连接的水溶性聚合物改性的蛋白质强制释放水溶性聚合物如聚乙二醇（PEG）和聚唾液酸（PSA）的体外测定系统的开发。 本发明包括用于分析水溶性聚合物的释放并测量重新获得的蛋白质活性的方法。 本发明还包括适用于用可释放水溶性聚合物（包括聚合物如PEG和PSA）改性的蛋白质的质量控制的方法。
-
公开(公告)号：US08546332B2
公开(公告)日：2013-10-01
申请号：US12388665
申请日：2009-02-19
申请人： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
发明人： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
CPC分类号： C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
摘要： Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
-
24.发明授权Modified recombinant factor VIII and von Willebrand factor and methods of use 有权修饰重组因子VIII和von Willebrand因子及其使用方法公开(公告)号：US08173597B2
公开(公告)日：2012-05-08
申请号：US12267491
申请日：2008-11-07
申请人： Hans-Peter Schwarz , Peter Turecek
发明人： Hans-Peter Schwarz , Peter Turecek
IPC分类号： A61K38/37 , C07K14/775
CPC分类号： A61K38/37 , A61K47/60 , A61K47/61 , C07K14/755 , C08G65/329 , C08H1/00 , C08L63/00 , C08L2203/02
摘要： The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
摘要翻译： 本发明提供了通过抑制与间隙受体的相互作用来增加凝血蛋白的存活的新方法。 本发明还提供了制备抑制凝血蛋白清除受体的组合物的方法。 共轭凝血蛋白，包括其组合物和制剂，也由本发明提供。
-
25.发明申请METHODS FOR DIFFERENTIATING PLASMA- DERIVED PROTEIN FROM RECOMBINANT PROTEIN IN A SAMPLE 有权从样品中重组蛋白质分离衍生的蛋白质的方法公开(公告)号：US20120040379A1
公开(公告)日：2012-02-16
申请号：US13281519
申请日：2011-10-26
申请人： Alfred Weber , Peter Turecek , Hans-Peter Schwarz
发明人： Alfred Weber , Peter Turecek , Hans-Peter Schwarz
IPC分类号： G01N33/577 , G01N33/82 , G01N33/573 , G01N33/53
CPC分类号： G01N33/6842 , G01N2333/4724 , G01N2333/755 , Y10S436/827 , Y10T436/10 , Y10T436/105831 , Y10T436/106664
摘要： The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
摘要翻译： 本发明一般涉及当血浆蛋白质和重组蛋白质基本上相同的蛋白质时，基于蛋白质糖基化的差异，在样品中检测和定量血浆衍生的蛋白质和重组蛋白质的方法。
-
公开(公告)号：US20090304669A1
公开(公告)日：2009-12-10
申请号：US12124390
申请日：2008-05-21
CPC分类号： C12N9/6454 , B01D15/363 , C12Y304/21075
摘要： Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.
摘要翻译： 重组截短的人弗林蛋白酶在CHO细胞中表达，并通过超滤和渗滤浓缩约50倍。 浓缩物通过Capto-MMC TM上的柱色谱纯化，得到30-50倍纯化因子，产率至少为60％。 在Capto-MMC TM色谱上获得的至少20％的纯制剂已经具有允许亲VWF的柱上成熟的纯化程度。 然后进行额外的精氨酸琼脂糖层析纯化。 用于纯化截短的人弗林蛋白酶的这种两柱方法产生几乎纯的弗林蛋白酶制剂，其具有约290,000U弗林蛋白/ mg蛋白质的比活性，约50％的产率。
-
27.发明申请MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE 有权改性重组因子VIII和VON WILLEBRAND因子及其使用方法公开(公告)号：US20090247459A1
公开(公告)日：2009-10-01
申请号：US12267491
申请日：2008-11-07
申请人： Hans-Peter Schwarz , Peter Turecek
发明人： Hans-Peter Schwarz , Peter Turecek
CPC分类号： A61K38/37 , A61K47/60 , A61K47/61 , C07K14/755 , C08G65/329 , C08H1/00 , C08L63/00 , C08L2203/02
摘要： The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
摘要翻译： 本发明提供了通过抑制与间隙受体的相互作用来增加凝血蛋白的存活的新方法。 本发明还提供了制备抑制凝血蛋白清除受体的组合物的方法。 共轭凝血蛋白，包括其组合物和制剂，也由本发明提供。
-
公开(公告)号：US07544660B2
公开(公告)日：2009-06-09
申请号：US10986281
申请日：2004-11-12
申请人： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
发明人： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
CPC分类号： C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
摘要： Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
摘要翻译： 具有FVIII：C活性的因子VIII多肽，其含有因子VIII轻链序列的A3和/或C1和/或C2结构域的修饰，其特征在于与低密度脂蛋白受体蛋白的结合亲和力，以及生产方法 一样。
-
公开(公告)号：US20060160994A1
公开(公告)日：2006-07-20
申请号：US10986281
申请日：2004-11-12
申请人： Petrus Lenting , Jan Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
发明人： Petrus Lenting , Jan Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
IPC分类号： C07K14/775
CPC分类号： C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
摘要： Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
-
30.发明授权
公开(公告)号：US6013620A
公开(公告)日：2000-01-11
申请号：US926845
申请日：1997-09-11
申请人： Peter Turecek , Hans-Peter Schwarz , Gerda Redl
发明人： Peter Turecek , Hans-Peter Schwarz , Gerda Redl
IPC分类号： A61K38/04 , A61K38/43 , A61K38/46 , A61K38/48 , A61P7/02 , C12N9/64 , A61K35/14 , A61K38/16 , C07K14/745
CPC分类号： C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021 , Y10S514/834
摘要： The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition as a FEIB-activity and is characterized in that it has Factor VIIa and at least one further active ingredient and the activity of at least 10 Factor VIIa units per unit FEIBA. Additionally, the invention comprises a method for the production of the pharmaceutical preparation and its use.
摘要翻译： 本发明涉及一种用于治疗由凝血因子缺乏引起的凝血疾病患者和/或凝血因子抑制剂的药物组合物，其中组合物作为FEIB活性，其特征在于其具有因子VIIa和 至少一种其他活性成分和至少10个因子VIIa单位每单位FEIBA的活性。 此外，本发明包括制备药物制剂及其用途的方法。
-
-
-
-
-
-
-
-
-
搜索结果
149 条记录 (耗时 0.04 秒)
